The market size value per capita of penicillins and streptomycins in bulk in China showed a consistent upward trend from 2024 through 2028. In 2023, the value stood at $0.063. From 2024 to 2025, there is a year-on-year increase of 3.08%, and from 2025 to 2026, a similar increase of 2.99%. For 2026 to 2027, the growth is 1.45%, while from 2027 to 2028, a 2.86% rise is projected. The compound annual growth rate (CAGR) over this five-year period is expected to be approximately 2.88% annually, reflecting steady growth.
Trends to watch for in the future include:
- Potential market impacts from regulatory changes affecting China’s pharmaceutical industry.
- The influence of technological advancements in antibiotic production and distribution.
- Shifts in global demand and competition affecting local prices and market dynamics.
- The impact of healthcare reforms in China on drug demand and market consumption patterns.
